Plus, news about CAMP4 Therapeutics, Serina Therapeutics, Kriya Therapeutics, Cutiss, Dianthus Therapeutics, Alnylam and Eyexora:
🔬 PMV touts Phase 2 data in p53 mutation cancers: In a 97-patient trial for rezatapopt, PMV
↧